FIELD: medicine; oncology.
SUBSTANCE: invention is intended for the treatment of breast cancer in an individual. A method of treating breast cancer in an individual in need thereof comprises administering to the individual of a CXCR7 inhibitor, wherein the individual has aberrant expression of FRS2β and wherein the CXCR7 inhibitor has the structure of Formula I or pharmaceutically acceptable salts thereof or Formula II or pharmaceutically acceptable salts thereof, wherein the radicals are as stated.
EFFECT: use of the invention provides treatment for breast cancer in an individual.
9 cl, 6 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS OF TREATING CANCER | 2016 |
|
RU2729396C2 |
| COMBINATION THERAPY USING CC CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE CHECKPOINT INHIBITORS | 2019 |
|
RU2810717C2 |
| REDUCTION OF TUMOR MASS BY INJECTING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | 2017 |
|
RU2745195C2 |
| METHODS OF TREATING CANCER | 2013 |
|
RU2677276C2 |
| COMBINATION THERAPY WITH A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | 2018 |
|
RU2796863C2 |
| COMPOUND FOR TREATING CANCER | 2014 |
|
RU2708247C2 |
| METHODS AND COMPOSITIONS FOR TREATING TUMORS | 2017 |
|
RU2741786C2 |
| AXL SIGNALLING INHIBITION IN ANTIMETASTATIC THERAPY | 2011 |
|
RU2556822C2 |
| MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE-3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | 2013 |
|
RU2665949C2 |
| 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN TREATMENT OF TUMOURS | 2015 |
|
RU2712950C2 |
